In yesterday’s Wall Street session, Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares traded at $0.18, down -5.42% from the previous session.
PIRS stock price is now 5.54% away from the 50-day moving average and -24.99% away from the 200-day moving average. The market capitalization of the company currently stands at $18.11M.
With the price target maintained at $5, Robert W. Baird recently Upgraded its rating from Neutral to Outperform for Pieris Pharmaceuticals Inc (NASDAQ: PIRS). , while ‘Jefferies’ rates the stock as ‘Buy’
In other news, KIRITSY CHRISTOPHER P, Director bought 10,000 shares of the company’s stock on May 25 ’23. The stock was bought for $8,500 at an average price of $0.85. Upon completion of the transaction, the Director now directly owns 20,000 shares in the company, valued at $3600.0. A total of 7.45% of the company’s stock is owned by insiders.
During the past 12 months, Pieris Pharmaceuticals Inc has had a low of $0.14 and a high of $1.52. As of last week, the company has a debt-to-equity ratio of 0.40, a current ratio of 2.05, and a quick ratio of 2.05. The fifty day moving average price for PIRS is $0.1736 and a two-hundred day moving average price translates $0.2443 for the stock.
The latest earnings results from Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at $0.04, beating analysts’ expectations of -$0.11 by 0.15. This compares to -$0.13 EPS in the same period last year. The net profit margin was -59.25% and return on equity was -84.68% for PIRS. The company reported revenue of $19.52 million for the quarter, compared to $5.37 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 263.5 percent. For the current quarter, analysts expect PIRS to generate $2.24M in revenue.
